(R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: A role of gut–microbiota–brain axis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is the most common demyelinating disease that attacks the central nervous system. We recently reported that the new antidepressant (R)-ketamine could ameliorate the disease progression in experimental autoimmune encephalomyelitis model of MS. Cuprizone (CPZ) has been used to produce demyelination which resembles demyelination in MS patients. This study was undertaken to investigate whether (R)-ketamine could affect demyelination in CPZ-treated mice and remyelination after CPZ withdrawal. Repeated treatment with (R)-ketamine (10 mg/kg/day, twice weekly, for 6 weeks) significantly ameliorated demyelination and activated microglia in the brain compared with saline-treated mice. Furthermore, pretreatment with ANA-12 (TrkB antagonist) significantly blocked the beneficial effects of (R)-ketamine on the demyelination and activated microglia in the brain of CPZ-treated mice. The 16S rRNA analysis showed that (R)-ketamine significantly improved abnormal composition of gut-microbiota and decreased levels of lactic acid of CPZ-treated mice. In addition, there were significant correlations between demyelination (or microglial activation) in the brain and the relative abundance of several microbiome, suggesting a link between gut microbiota and brain. Interestingly, (R)-ketamine could facilitate remyelination in the brain after CPZ withdrawal. In conclusion, the study suggests that (R)-ketamine could ameliorate demyelination in the brain of CPZ-treated mice through TrkB activation, and that gut-microbiota-microglia crosstalk may play a role in the demyelination of CPZ-treated mice. Therefore, it is likely that (R)-ketamine could be a new therapeutic drug for MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
Regenerating CNS myelin — from mechanisms to experimental medicines
Franklin, R. J. M., & ffrench-Constant, C. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.136 · Cited by 647 · cited 1×
“After CPZ withdrawal, spontaneous remyelination was shown in CPZ-treated mice (Franklin and Ffrench-Constant, 2017; Torkildsen et al., 2008).”
BackgroundR-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationKetogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
Ferrere, G., Tidjani Alou, M., Liu, P., Goubet, A.-G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillère, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145207 · Cited by 533
Microglia in Central Nervous System Inflammation and Multiple Sclerosis Pathology
Voet, S., Prinz, M., & van Loo, G. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.005 · Cited by 503 · cited 1×
“Multiple lines of evidence suggest a key role of microglia in the pathology of MS (Chu et al., 2018; Deng and Sriram, 2005; Gao and Tsirka, 2011; Guerrero and Sicotte, 2020; Rawji and Young, 2013; Voet et al., 2019).”
BackgroundMicrobiome–microglia connections via the gut–brain axis
Abdel-Haq, R., Schlachetzki, J. C. M., Glass, C. K., & Mazmanian, S. K. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180794 · Cited by 471
Gut microbiota in multiple sclerosis: possible influence of immunomodulators
Cantarel, B. L., Waubant, E., Chehoud, C., Kuczynski, J., DeSantis, T. Z., Warrington, J., Venkatesan, A., Fraser, C. M., & Mowry, E. M. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000192 · Cited by 409 · cited 2×
“evidence shows the role of gut microbiota in pathogenesis of MS (Cantarel et al., 2015; Cekanaviciute et al., 2017; Farshbafnadi et al., 2021; Ghezzi et al., 2021; Maghzi and Weiner, 2020; Parodi and Kerlero de Rosbo, 2021; The iMSMS Consortium, 2020).”
BackgroundR (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Self-citationThe cuprizone model for demyelination
Torkildsen, Ø., Brunborg, L. A., Myhr, K.-M., & Bø, L. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01036.x · Cited by 346
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335 · cited 3×
“Collectively, it is possible that gut microbiota may play a role in the beneficial actions of (R)-ketamine (Hashimoto, 2019; Hashimoto, 2020; Wei et al., 2021a) although further study is needed.”
BackgroundSelf-citationPharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271 · cited 1×
“Interestingly, side effects of (R)-ketamine in animals and humans were lower than those of (R,S)ketamine and (S)-ketamine (Bonaventura et al., 2021; Chang et al., 2019; Hashimoto et al., 2017; Leal et al., 2021; Tan and Hashimoto, 2020; Tian et al., 2018; Yang et al., 2015; Yang et al., 2016b).”
BackgroundIntravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Self-citationThe benefits and detriments of macrophages/microglia in models of multiple sclerosis
Rawji, K. S., & Yong, V. W. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/948976 · Cited by 217
Microglial ERK-NRBP1-CREB-BDNF Signaling in Sustained Antidepressant Actions of (R)-Ketamine
Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01377-7 · Cited by 216
Self-citationMicroglia in multiple sclerosis: Friend or foe
Guerrero, B. L., & Sicotte, N. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00374 · Cited by 215 · cited 1×
“…it is likely that (R)-ketamine would be a potential therapeutic drug for MS. Multiple lines of evidence suggest a key role of microglia in the pathology of MS (Chu et al., 2018; Deng and Sriram, 2005; Gao and Tsirka, 2011; Guerrero and Sicotte, 2020; Rawji and Yong, 2013; Voet et al., 2019).”
BackgroundThe Cuprizone Model: Dos and Do Nots
Zhan, J., Mann, T., Joost, S., Behrangi, N., Frank, M., & Kipp, M. (2020) · Cells · doi:10.3390/cells9040843 · Cited by 208
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Self-citationZhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., & Hashimoto, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4062-3 · Cited by 183
Self-citationChang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176 · cited 4×
“depression in MS patients using the novel antidepressant (R)-ketamine (Hashimoto, 2019; Hashimoto, 2020; Wei et al., 2021a).”
BackgroundMethodInfluentialSelf-citationHashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0692-7 · Cited by 127
Self-citationGut microbiota–driven brain Aβ amyloidosis in mice requires microglia
Dodiya, H. B., Lutz, H. L., Weigle, I. Q., Patel, P., Michalkiewicz, J., Roman-Santiago, C. J., Zhang, C. M., Liang, Y., Srinath, A., Zhang, X., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20200895 · Cited by 120
Zhang, K., Yang, C., Chang, L., Sakamoto, A., Suzuki, T., Fujita, Y., Qu, Y., Wang, S., Pu, Y., Tan, Y., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0733-x · Cited by 119
Self-citationYang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4399-2 · Cited by 91
Self-citationYang, C., Han, M., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.03.034 · Cited by 91 · cited 2×
“Second, (R)-ketamine is reported to stimulate phosphorylation of TrkB, resulting in its pharmacological effects (Tan et al., 2020; Yang et al., 2015; Yang et al., 2016a).”
BackgroundSelf-citationZhang, K., Sakamoto, A., Chang, L., Qu, Y., Wang, S., Pu, Y., Tan, Y., Wang, X., Fujita, Y., Ishima, T., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01092-z · Cited by 63
Self-citationXiong, Z., Fujita, Y., Zhang, K., Pu, Y., Chang, L., Ma, M., Chen, J., & Hashimoto, K. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111904 · Cited by 49 · cited 1×
“Increasing preclinical findings demonstrated that the new antidepressant (R)-ketamine, (R)-enantiomer of (R,S)-ketamine, has potent anti-inflammatory effects in several animal models (Fujita and Hashimoto, 2020; Fujita et al., 2020; Fujita et al., 2021; Qu et al., 2021; Xiong et al., 2019; Yang et al., 2015; Yang et a…”
BackgroundSelf-citation
Cited by
Brain-spleen axis in health and diseases: A review and future perspective
Wei, Y., Wang, T., Liao, L., Fan, X., Chang, L., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.008 · Cited by 134
Self-citationMotor Behavioral Deficits in the Cuprizone Model: Validity of the Rotarod Test Paradigm
Lubrich, C., Giesler, P., & Kipp, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911342 · Cited by 77
Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model
Leo, H., & Kipp, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416093 · Cited by 46
Metadata
- Authors
- Wang, X., Chang, L., Wan, X., Tan, Y., Qu, Y., Shan, J., Yang, Y., Ma, L., & Hashimoto, K.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 165
- Pages
- 105635
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W4206920503
- Cited by
- 64
- References
- 27
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.